Navigation Links
American Heart Association Journal Report: Surgical Residents Perform Heart Surgery as Effectively as Staff Surgeons
Date:9/30/2008

rgery -- 58.6 percent for staff cases vs. 55.8

percent for resident cases.

None of these differences were statistically significant after considering that as a group the patients operated on by residents as primary surgeons were sicker.

The average follow-up time was three years, with a maximum of eight years.

Baskett emphasized the importance of supervised training of surgical residents, especially for the benefit of future generations of heart surgery patients.

"The important message is that it is safe to train residents if they are appropriately supervised," Baskett said. "It is not only safe, even with complex procedures, but it is very important. That should make patients very comfortable. It is critical that trainees operate because they're going to be the ones operating on the next generation -- your kids."

The National Center for Health Statistics estimates that in 2005, 469,000 CABG procedures were performed on 261,000 patients in the United States and there were 106,000 valve replacements.

Co-authors are: Serban C. Stoica, M.D.; Dimitri Kalavrouziotis, M.D.; Billie-Jean Martin, M.D.; Karen J. Buth, M.Sc.; Gregory Hirsch, M.D.; and John A. Sullivan, M.D. Individual author disclosures can be found on the manuscript.

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are avail
'/>"/>

SOURCE American Heart Association
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. International Medical Corps Matched with Top 25 American Express Members Project, Saving the Lives of Malnourished Children
2. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
3. Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
4. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. American Lung Association Study Finds No Evidence of Depression or Suicide Linked to Asthma and Allergy Drug Montelukast
7. Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent
8. Alzheimers Foundation of America Survey: Americans With Memory Concerns Fall Short of Talking to Doctors
9. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
10. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
11. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2008)...che- , , MONTVALE, N.J., Nov. 19 /PRNewswir...aq: MEMY ) today announced that it has achieved .../MEM 3454, its lead alpha-7 nicotinic receptor ago...zophrenia (CIAS). The Company has randomized 212 ...illion payment from its partner Roche. Memory Pha...
(Date:11/18/2008)...arn more, make a donation or send a Christmas Seal...e-USNewswire/ -- Millions will receive Christmas S...can Lung Association. These decorative holiday sta...ting back to 1907 when the Lung Association led ef...Americans alive today have no vivid memories of ho...
(Date:11/18/2008)...USNewswire/ -- Forty-two leading U. S. scientists ...rum to consider cutting-edge innovations that may ...y from outbreaks of dangerous zoonotic diseases, t...hose innovations: , , , , A "Do...etects highly contagious and dangerous zoonotic di...
(Date:11/18/2008)...iagnosed, elderly AML patients , , PRINCETO...ticals today announced that the first patient has ...y of CPX-351 (Cytarabine:Daunorubicin) Liposome In...loid leukemia (AML). , , The first patient ...ical College of Cornell University and New York P...
Breaking Medicine Technology:Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3American Lung Association Celebrates 101st Annual Christmas Seals Campaign 242 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 2Celator(R) Pharmaceuticals Announces Enrollment of First Patient in Phase 2 Study with CPX-351 3Dendreon to Hold a Conference Call Today at 9 3A00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 3211 1Dendreon to Hold a Conference Call Today at 9 3A00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 3211 2Global Sourcing Strategies for the Pharmaceutical Industry 10th 11th November Marriott Princeton New Jersey USA 27033 1Global Sourcing Strategies for the Pharmaceutical Industry 10th 11th November Marriott Princeton New Jersey USA 27033 2Academic Medicine Means Business for Ohio 3A 2437 2 Billion Economic Impact for the State 27032 1Academic Medicine Means Business for Ohio 3A 2437 2 Billion Economic Impact for the State 27032 2Concord Grape Juice Has No Significant Impact on Body Weight 3209 1Concord Grape Juice Has No Significant Impact on Body Weight 3209 2Concord Grape Juice Has No Significant Impact on Body Weight 3209 3
... of market dynamics offers insights into,what will...to,patients, NEW YORK, May 14, 2007 /PRNewswire-US...pment (TB Alliance), a not-for-profit,product dev...d,development of new TB drugs, today released resu...mics of the global TB drug market,that offers a de...
...pitalization and drug withdrawal, CHICAGO, May 15,...migraine patients and physicians commissioned by t...arris Interactive shows that,20 percent of migrain...ive medications that contain barbiturates or opioi... Drug Administration for the,relief of migraines. ...
Other Medicine Technology:New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 2New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 3New Study Reveals Limitations of a Complex and Challenging Global,Tuberculosis Drug Marketplace 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 2Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 3Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 5Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 6
(Date:11/21/2008)...apies for preterm labor , , FRIDAY, Nov....und the switch that activates the uterine muscles ...may lead to therapies for preterm labor. , The...IP on the surface of these uterine muscle cells, k..., But researchers from Dartmouth Medical Schoo...
(Date:11/21/2008)...ers to be held on January 8, 2009 , , TORON...ernational Inc. ("MedEmerg") (OTCBB: MDER), one of...nounced today that it has obtained an interim orde...rning its previously announced plan of arrangement...Group Inc. ("AIM") will acquire all of MedEmerg,s ...
(Date:11/21/2008)...niversity of Texas Health Science Center at Housto...n Aging Studies (TEXAS), to promote geriatrics tra...ion award from the Donald W. Reynolds Foundation a...llow us to teach geriatric medicine principles to ...racticing physicians. With the reach of Lyndon B. ...
(Date:11/21/2008)...Newswire-FirstCall/ -- Heska Corporation,(Nasdaq:...ew York Society of,Security Analysts, 12th Annual...ber 2, 2008 at 1177 Avenue of the Americas, 2nd Fl...d to begin at 9:35 a.m. Eastern Time (7:35 a.m.,M...st and for two weeks,following the presentation t...
Breaking Medicine News(10 mins):Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 2Health News:Med-Emerg International Inc. obtains interim court order for plan of arrangement with AIM Health Group Inc. 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4
...tudy has revealed that anti-depressants like Fluox... damage upon the human skeleton.// The Norwegian U...rcher Bjorn I. Gustafsson has revealed that anti-d...ty of bone building cells, while raising the produ...
...rom University of North Carolina have identified a...ng the activity of Tumor// suppressor protein. Tum...ng the integrity of cell and prevents the cell fro...h of cell. Ack1 is found to be a growth promoting ...
... has lifted the ban on the import of poultry produ... of bird flu strain //for the second time in a mon...n follows identifying that both the isolated virus... is found to be a non-infectious and less pathogen...
...ey has revealed that about 6 out of 10 parents of ...ctivity Disorder (ADHD) are not getting// enough s...launched by the drugs firm Eli Lilly and National ...rmation and Support Service (ADDISS) is to help pa...
Other Medicine News:Health News:Gene responsible for developing prostate cancer identified 2
Weight: 10.1 kg, Interior Dimensions (WxDxH): 31.1 x 13.6 x 15.3 cm, Exterior Dimensions (WxDxH): 44.6 x 22.4 x 20.5 cm, Capacity: 4 - 50 mL conical tubes, 2 - 300 x 35 mm bottles, 4 - 150 x 35 mm b
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
...I system consists of four basic components: sample...and metal clamping plate (see diagram). The sample...or producing spots, dots, or slots (see below). Al...hased as an accessory plate in conjunction with a ...
Medicine Products: